Entrectinib

Targeted Therapy

National Cancer Center, ChinaSmall moleculeActive

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 89/ 100

Competitive context

15 Active assets in the Targeted Therapy cohort.

Asset / Sponsor	Phase	Rating
(+)-VINCRISTINE Sun Yat-sen University	Phase 2	B
Irinotecan Sun Yat-sen University	Phase 2	B
Trifluorouracil Tepidopyrimidine Sun Yat-sen University	Phase 2	CCC
Epirubicin Peking University First Hospital	Phase 2	CCC
Axitinib Peking University First Hospital	Phase 2	CCC

View all 18 →

Same molecule, other indications

Entrectinib is also rated in:

hematopoietic and lymphoid system neoplasmDormant

BB

Indicative ·

64 / 100

Anatomic Stage IV Breast Cancer AJCC v8Dormant

B

Indicative ·

62 / 100

sarcomaDormant

B

Indicative ·

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.